-
Tytuł:
-
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
-
Autorzy:
-
Friedlaender, Alex
Metro, Giulio
Signorelli, Diego
Gili, Alessio
Economopoulou, Panagiota
Roila, Fausto
Banna, Giuseppe
De Toma, Alessandro
Camerini, Andrea
Christopoulou, Athina
Lo Russo, Giuseppe
Banini, Marco
Galetta, Domenico
Jimenez, Beatriz
Collazo-Lorduy, Ana
Calles, Antonio
Baxevanos, Panagiotis
Linardou, Helena
Kosmidis, Paris
Mountzios, Giannis
-
Temat:
-
CANCER patients
COMPARATIVE studies
CONFIDENCE intervals
LUNG cancer
MEMBRANE proteins
MONOCLONAL antibodies
MULTIVARIATE analysis
SURVIVAL
TREATMENT effectiveness
RETROSPECTIVE studies
DESCRIPTIVE statistics
ODDS ratio
-
Źródło:
-
Acta Oncologica; Sep2020, Vol. 59 Issue 9, p1058-1063, 6p, 2 Charts, 1 Graph
-
Objectives: We retrospectively analysed patients with advanced non-small-cell lung cancer (NSCLC) harbouring high PD-L1 expression (>50%) and treated with front-line pembrolizumab, comparing outcomes of patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 to those with PS 0-1. Methods: Data were collected by 16 participating centres. All patients with NSCLC and high PD-L1, treated with first-line pembrolizumab were included. We collected medical data from patient files, pathology and laboratory reports. Patient characteristics, comorbidities, PS, and tumour characteristics were reported. Overall survival (OS), progression-free survival (PFS) and response rate (RR) were calculated. Results: 302 patients were included, 246 with PS 0-1, 56 with PS 2. RR was 72% among patients with PS 0-1 compared to 45% with PS2 (odds ratio (OR) 0.31 (95% CI: 0.17–0.57), p <.001). Median PFS was 2.6 months (95% CI: 1.9–5.1) among patients with PS2 and 11.3 months (95% CI: 8.5–14.4) among those with PS 0-1. Median OS was 7.8 months (95% CI: 2.5–10.7) in the PS2 group, not reached in the PS 0-1 group. PS 2 remained predictive of poor outcomes in multivariate analysis. Conclusion: PS 2 is a strong independent predictor of poor response and survival in NSCLC patients with high PD-L1, treated with front-line pembrolizumab. Prospective randomised trials comparing immunotherapy to chemotherapy in this population would be welcome. [ABSTRACT FROM AUTHOR]
Copyright of Acta Oncologica is the property of Medical Journals Sweden AB and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.